Skip to main content

Advertisement

SpringerLink
Log in

Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All patients had relapsed after only one prior chemotherapy regimen (CHOP — 56%; mBACOD — 28%). There were three complete and eight partial responses (overall response rate — 34%) among 32 eligible patients. The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 patients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia.

We conclude that mitoxantrone-cisplatin-MGBG has modest activity as salvage treatment in malignant lymphoma patients, but produces severe toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Skarin AT, Canellos GP, Rosenthal DS, Case DC, Pinkus GS, Harrington DP: Moderate dose m-BACOD in advanced diffuse large cell lymphoma: An interim report. Adv Cancer Chemother, pp 23–30, 1986

  2. Fisher RI, DeVita VT, Longo DL, Young RC: Treatment of diffuse aggressive lymphoma with PROMACE-based combination chemotherapy. Adv Cancer Chemother, pp 31–36, 1986

  3. Connors JM, Klimo P: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma: 1985 update. Adv Cancer Chemother, pp 37–44, 1986

  4. Schein PS, DeVita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RD: Bleomycin, Adriamycin, cyclophosphamide, vincristine, and Prednisone combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 95:417–422, 1976

    Google Scholar 

  5. Sweet DL, Golomb HM, Ultmann JE, Miller JB, Stein RS, Lester EP, Mintz U, Bitran JB, Stremli RA, Daly K, Roth NO: Cyclophosphamide, vincristine, methotrexate, with leucovorin rescue, and cytarabine combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 92:785–790, 1980

    Google Scholar 

  6. Kantarjian H, Barlogie B, Plunkett W, Valasquez W, McLaughlin P, Riggs S, Cabanillas F: High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Onc 1:689–694, 1983

    Google Scholar 

  7. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ: IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693–697, 1982

    Google Scholar 

  8. Ng RP, Todd D, Khoor KK: Salvage chemotherapy for non-Hodgkin's lymphoma. Cancer Treat Rep 66:1977–1979, 1982

    Google Scholar 

  9. Warrell RP, Straus DJ, Young CW: Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and Teniposide (VM-26). Cancer Treat Rep 66:1121–1125, 1981

    Google Scholar 

  10. Heinz R, Dittrich CH, Ludwig H, Kuhbock J, Wirth M, Baumgartner G, Waldner R, Schuller J: Results of a new combination chemotherapy (VIM-Bleo) in advanced non-Hodgkin's lymphomas. (Abstr) Proc Am Soc Clin Oncol 6:191, 1987

    Google Scholar 

  11. Dana BW, Jones SE, Coltman C, Stuckey WI: A phase II trial of m-AMSA, Cis-platinum, and MGBG in refractory lymphomas. Cancer Treat Rep 70:291–292, 1986

    Google Scholar 

  12. Van Echo DA, Whitacre MY, Aisner J, Wiernik PH: Phase I trial of dihydroxyanthracenedione. Cancer Treat Rep 65:831–834, 1981

    Google Scholar 

  13. Coltman CA, McDaniel TM, Balcerzak SP, Morrison FS, VonHoff DD: Mitoxantrone hydrochloride in lymphoma. Invest New Drugs 1:65–70, 1983

    Google Scholar 

  14. Corbett TH, Robert BJ, Trader MW, Laster WR, Griswold DP, Schabel FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66:1187–1200, 1982

    Google Scholar 

  15. Miller AB, Hoogstratten B, Stagnet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    CAS  PubMed  Google Scholar 

  16. Warrell RP, Danieu L, Coonley CJ, Atkins C: Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate, and etoposide. Cancer Treat Rep 71:47–51, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oregon Health Sciences University, USA

    Bruce Dana

  2. Southwest Oncology Group Statistical Center, Seattle, USA

    Steve Dahlberg

  3. University of Michigan Medical Center, USA

    Bertram Schnitzer

  4. University of Utah Medical Center, USA

    Carl R. Kjeldsberg

  5. Arizona Cancer Center, USA

    Stephen E. Jones

  6. St. Louis CCOP, USA

    Juan Carden

  7. Midwest CCOP, USA

    Richard Mundis

  8. Arkansas CCOP, USA

    Bill Tranum

Authors
  1. Bruce Dana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve Dahlberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bertram Schnitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carl R. Kjeldsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen E. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Juan Carden
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Mundis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bill Tranum
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Southwest Oncology Group (SWOG-8369), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dana, B., Dahlberg, S., Schnitzer, B. et al. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial. Invest New Drugs 7, 247–250 (1989). https://doi.org/10.1007/BF00170868

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00170868

Key words

Search

Navigation